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Abstract
Background Several anthropometric measures have been
found to be associated with the risk of breast cancer. Current
weight, body mass index, and adult weight gain appear to be
predictors of postmenopausal breast cancer. These factors
have been associated with a reduced risk of premenopausal
breast cancer. We asked whether there is an association
between changes in body weight and the risk of breast cancer
in women who carry a mutation in either breast cancer
susceptibility gene, BRCA1 or BRCA2.
Methods A matched case–control study was conducted in
1,073 pairs of women carrying a deleterious mutation in either
BRCA1 (n = 797 pairs) or BRCA2 (n = 276 pairs). Women
diagnosed with breast cancer were matched to control subjects
by year of birth, mutation, country of residence, and history of
ovarian cancer. Information about weight was derived from a
questionnaire routinely administered to women who were
carriers of a mutation in either gene. Conditional logistic
regression was used to estimate the association between
weight gain or loss and the risk of breast cancer, stratified by
age at diagnosis or menopausal status.
Results A loss of at least 10 pounds in the period from age 18
to 30 years was associated with a decreased risk of breast
cancer between age 30 and 49 (odds ratio (OR) = 0.47; 95%
confidence interval (CI) 0.28–0.79); weight gain during the
same interval did not influence the overall risk. Among the
subgroup of BRCA1 mutation carriers who had at least two
children, weight gain of more than 10 pounds between age 18
and 30 was associated with an increased risk of breast cancer
diagnosed between age 30 and 40 (OR = 1.44, 95% CI 1.01–
2.04). Change in body weight later in life (at age 30 to 40) did
not influence the risk of either premenopausal or
postmenopausal breast cancer.
Conclusion The results from this study suggest that weight loss
in early adult life (age 18 to 30) protects against early-onset
BRCA-associated breast cancers. Weight gain should also be
avoided, particularly among BRCA1 mutation carriers who elect
to have at least two pregnancies.
BRCA1 = breast cancer susceptibility gene 1; BRCA2 = breast cancer susceptibility gene 2; CI = confidence interval; IGF-1 = insulin-like growth 
factor 1; OR = odds ratio.Breast Cancer Research    Vol 7 No 5    Kotsopoulos et al.
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Introduction
The inheritance of a deleterious mutation in either of the two
breast cancer susceptibility genes, BRCA1 or BRCA2, has
been associated with a lifetime risk of breast cancer of 45% to
87% [1,2]. Reports of increasing penetrance among women
born in recent cohorts in comparison with those born in earlier
years has prompted the search for factors that may influence
the risk of cancer in genetically susceptible women [2-5]. To
date, both genetic and non-genetic factors have been sug-
gested to influence breast cancer risk in BRCA1 and BRCA2
mutation carriers, and many implicate estrogen-induced stim-
ulation as a probable contributor (reviewed in [6]). Genetic risk
factors include both the type and position of the mutation [7-
9], as well as the presence of specific alleles of modifying
genes [10-13]. Non-genetic or environmental factors include
hormonal factors, in particular those related to estrogen expo-
sure (reviewed in [6]). Reproductive factors that modify risk in
BRCA carriers include breastfeeding, parity, and oral contra-
ceptive use (reviewed in [14]).
The worldwide prevalence of obesity is rising [15]. Evidence
from animal studies suggests that positive energy balance has
a growth-promoting effect on tumours [16]. Numerous epide-
miological studies have evaluated the role of various anthropo-
metric risk factors in the etiology of breast cancer (reviewed in
[17]). Collectively, the evidence suggests that the effects of
body mass index (BMI) and of adult weight gain on the risk of
breast cancer are dependent on menopausal status at diagno-
sis. There appears to be an inverse relation between both BMI
and weight and the risk of premenopausal breast cancer;
whereas there is a positive association between body weight,
BMI, and adult weight gain on the risk of breast cancer after
the menopause (reviewed in [17-20]). Birthweight and adult
height have been associated with an increased risk of breast
cancer in both menopausal strata (reviewed in [17-20]).
Weight change that occurs at the time a woman is undergoing
hormonal changes (i.e. puberty, pregnancy, menopause) has
also been suggested to have an effect on risk [21,22].
Although various biological mechanisms by which weight may
influence breast cancer risk have been proposed (reviewed in
[17]), of particular relevance is an increase in circulating
endogenous sex hormones, particularly estrogen [23]. Epide-
miologic observations and laboratory studies suggest that sex
hormones play an important role in BRCA-carcinogenesis and
the current chemopreventive options available for BRCA car-
riers are based on the interruption of the estrogen-signalling
pathway (reviewed in [6,24]).
Studies are needed to determine if the known anthropometric
risk factors for sporadic breast cancer may also influence the
penetrance of breast cancer in BRCA carriers. We performed
a matched case–control study to investigate whether or not
there is an association between changes in body weight and
the risk of breast cancer in women with a deleterious BRCA1
or BRCA2 mutation. The identification of non-genetic modifi-
ers of risk may be useful for preventing hereditary breast
cancer.
Materials and methods
Study population and design
Eligible study subjects included women who were alive and
known to be carriers of deleterious mutations of the BRCA1
or BRCA2 gene. These women were identified from 41 partic-
ipating centers in five countries and were participants in previ-
ous and ongoing clinical research protocols at the host
institutions. All study subjects received counselling and gave
their written informed consent for genetic testing.
The study was approved by the institutional review boards of
the host institutions. In most cases, testing was initially offered
to women who had been affected with breast or ovarian can-
cer. When a BRCA1 or BRCA2 mutation was identified in a
proband or her relative, genetic testing was offered to other at-
risk women in the family. Mutation detection was performed
using a range of techniques, but all nucleotide sequences
were confirmed by direct sequencing of DNA. A woman was
eligible for the current study when the molecular analysis
established that she was a carrier of a pathogenic mutation.
Most (>95%) of the mutations identified in the study subjects
were nonsense mutations, deletions, insertions, or small
frameshifts.
There was information on cancer history and mutation carrier
status for a total of 3,291 women who carried BRCA1  or
BRCA2 mutations and who provided information on weight at
ages 18, 30, and 40. Potential case subjects were selected
from among the study subjects with a diagnosis of invasive
breast cancer. Case subjects were excluded if they had been
diagnosed with ovarian cancer (29 women) or any other form
of cancer (28 women) before being diagnosed with breast
cancer, or if information about their menopausal status was
missing (31 women). Control subjects were women who had
never had breast cancer and who were carriers of a mutation
in the BRCA1 or BRCA2 gene. A subject was not eligible to
be a control for a given case subject if she had had a protec-
tive bilateral mastectomy before the date of diagnosis in the
case (88 women). After exclusions, there was a total of 3,115
eligible women, including 1,471 women with breast cancer
(potential case subjects) and 1,644 women without breast
cancer (potential controls).
A single control subject was selected for each case subject,
matched according to mutation in the same gene (BRCA1 or
BRCA2), year of birth (within 1 year), and the country of resi-
dence. A diagnosis of ovarian or other form of cancer in the
control had to be after the year of diagnosis of breast cancer
of the matched case subject for her to be eligible. In addition,
the date of interview of the control was after the date of breast
cancer diagnosis of the matched case. A total of 1,073
matched case–control pairs was generated for the analysis,Available online http://breast-cancer-research.com/content/7/5/R833
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including 797 pairs with BRCA1 mutations and 276 pairs with
BRCA2 mutations. The 2,146 study subjects included in the
analysis were identified from 1,534 distinct families (1.4 sub-
jects per family). In the instance of 1,179 subjects, the subject
was the only member of the family to be included. These were
prevalent cases and had breast cancer before they knew their
mutation status. On average, 8.8 years had passed between
the subject's age at diagnosis (mean 39.8 years) and age at
interview (mean 48.6 years).
Data collection
Case and control subjects completed a questionnaire that
asked for relevant information regarding family history, repro-
ductive and medical histories, and selected lifestyle factors
including smoking history and use of oral contraceptives.
Questionnaires were administered by each of the individual
centers at the time of a clinic appointment or at their home at
a later date. Interviews occurred between 1988 and 2004 for
the case subjects and between 1994 and 2004 for the control
subjects. Additional variables of interest included information
on demography, ethnicity, and parity. Women were classified
as postmenopausal if they reported natural menopause and
had stopped menstruating, or if they had had a hysterectomy
and bilateral oophorectomy before the diagnosis of breast
cancer. Specifically for this study, the questionnaire asked for
information on height (in feet and inches) and weight (in
pounds). The participants were requested to think back to
when they were 18 years old (about the time they graduated
from high school) and to recall their weight then and subse-
quently at ages 30 and 40. Women were asked to report their
weight at birth, their current weight, and their height, as well as
the most they had ever weighed (excluding pregnancy). Only
case and control data before the time of the diagnosis of
breast cancer in the matched case were considered.
Anthropometric measures
We converted the reported weights from pounds to kilograms
and the heights from inches to meters for BMI calculations.
Variables that were created in this study included BMI (weight
(kg)/height(m2)) at ages 18, 30, and 40 years, and weight
change between age 18 and 30 and between 30 and 40 (cal-
culated as the difference between the weights at the age peri-
ods being compared).
Statistical analyses
A matched case – control analysis was performed to examine
the association between weight and changes in body weight,
and the risk of breast cancer. Because menopausal status has
been shown to modify the association between anthropomet-
ric factors and the risk of breast cancer, our analyses were
stratified according to menopausal status at the time the sub-
ject received a diagnosis of breast cancer diagnosis. Birth-
weight, height, weight, weight gain, and BMI were compared
between the case subjects and control subjects within each
stratum, using a paired t-test. This test statistic was also used
for all other continuous variables that were examined. The χ2
test was used to test for differences in categorical variables.
The univariate odds ratios (ORs), 95% confidence intervals
(CIs), and tests for linear trend were estimated by use of con-
ditional logistic regression. A multivariate analysis was also
carried out to control for the potential confounding effects of
oral contraceptive use, smoking, oophorectomy, and parity.
Smoking use was coded as 'ever' or 'never' smoker; oral con-
traceptive use was coded as 'ever' or 'never' user; oophorec-
tomy was coded as yes or no; and parity was coded as zero,
one, or two or more births. Weight change was categorized
into quartiles according to the distribution of the variables
among the controls.
The reference group were those women whose weight
remained stable (weight gain or loss of not more than 10
pounds from baseline). The weight-loss group included
women who lost at least 10 pounds. We examined the effect
of weight change between ages 18 and 30 and between ages
30 and 40 among subgroups defined according to the sub-
ject's age at diagnosis of the case. This effect was further eval-
uated according to mutation and menopausal status. There
were 26 menopausal case subjects who reported having had
a hysterectomy before their breast cancer had been diag-
nosed but who still had intact ovaries. These 26 pairs were
excluded from the subanalyses stratified by menopausal sta-
tus. Odds ratios were generated for these subgroups with the
matched-pair subsets. All statistical tests were two-sided. A P
value of <0.05 was taken to be significant. All analyses were
performed using the SAS statistical package, version 8.1
(SAS Institute, Cary, NC, USA).
Results
Study subjects
Case and control subjects were similar with regard to year of
birth, year of interview, current age, mutation status, smoking
history, and country of residence (Table 1). Oral contracep-
tives had been used by more of the case than control subjects
(P = 0.04), and parity was also slightly higher in the case than
control subjects (P = 0.06).
Comparison of anthropometric measures in BRCA1 or 
BRCA2 mutation carriers
Table 2 compares the mean values for various anthropometric
measures for the cases and controls as a whole, and stratified
by the menopausal status of the case subject when the breast
cancer was diagnosed. Among all the study participants, case
subjects weighed less at age 18 than the control subjects.
Among postmenopausal women, case subjects had a lower
BMI at age 18 than controls. There were no other statistically
significant differences between the case and control subjects
with respect to weight at birth, current height, weight, BMI, or
weight gain at various ages (Table 2).Breast Cancer Research    Vol 7 No 5    Kotsopoulos et al.
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The extent of weight gain experienced by our study subjects
varied according to their year of birth (Fig. 1). Those born in
earlier years experienced on average less weight gain
between age 18 and 30 and between 18 and 40 than women
born in later years. The increase in weight by calendar year is
most apparent at the ages of 30 and 40. There was also a sig-
Table 1
Comparison of subjects carrying BRCA mutations
Variable Control subjects (n = 1,073) Case subjects (n = 1,073) Pa
Age (years) at interview, no. (%)
≤ 30 17 (1.6) 26 (2.4)
31–40 219 (20.4) 242 (22.5)
41–50 415 (38.7) 386 (36.0)
51–60 277 (25.8) 264 (24.6)
≥ 61 145 (13.5) 155 (14.5) 0.32
Age (years) at interview, mean (SD) 47.9 (10.6) 48.6 (10.6) 0.25
Date of birth, mean year 1951.8 1951.2 0.14
Year of interview, mean (range) 1999.7 (1995–2004) 1999.8 (1999–2004) 0.18
Age (years) at diagnosis of breast cancer, no. (%)
≤ 30 NA 107 (10.0)
31–40 478 (44.5)
41–50 371 (34.5)
≥ 51 117 (10.9)
Age (years) at diagnosis of breast cancer, mean (SD) 39.8 (8.3)
Mutation, %
BRCA1 74.3 74.3
BRCA2 25.7 25.7
Parity
No. (%) parous 844 (79.6) 879 (82.8) 0.06
Parity, mean (SD) 1.9 (1.4) 1.9 (1.3) 0.18
No. (%) who ever used oral contraceptives 662 (62.6) 710 (66.8) 0.04
No. (%) who ever smoked 465 (43.3) 471 (43.9) 0.79
Country of residence at time of testing, no. (%)
Canada 420 (39.1) 420 (39.1)
Israel 20 (1.9) 20 (1.9)
UK 8 (0.8) 8 (0.8)
Poland 189 (17.6) 189 (17.6)
USA 436 (40.6) 436 (40.6)
aAll P values are univariate and were derived using Student's t-test for continuous variables and the χ2 test for categorical variables. NA, not 
applicable; SD, standard deviation.Available online http://breast-cancer-research.com/content/7/5/R833
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nificant difference between the mean weights at ages 18, 30,
and 40 among women residing in Canada, Poland, or the USA
(P = 0.0001, 0.02, and 0.02, respectively).
Changes in body weight between age 18 and 30 and risk 
of breast cancer in BRCA mutation carriers
To further examine the relationship between adult weight
change and the risk of breast cancer, we performed univariate
conditional logistic regression. The adjusted ORs were similar
to the unadjusted values; therefore, only univariate results are
reported here. As Table 3 shows, weight loss of at least 10
pounds between age 18 and 30 was associated with a signif-
icant reduction in breast cancer risk thereafter (OR = 0.66).
Weight gain during this period was not associated with
increased risk. However, stratification of the study subjects
according to their age at breast cancer diagnosis indicated
that changes in body weight appeared to have different effects
in carriers according to whether the breast cancer was diag-
nosed before or after age 40. Weight loss of at least 10
pounds was associated with a significant reduction in the risk
of breast cancer diagnosed between age 30 and 40 (OR =
0.47) (Table 3) but was not associated with the risk of breast
cancer diagnosed after age 40.
Subgroup analyses according to BRCA  mutation status
showed that among women with a BRCA1 mutation, weight
loss of at least 10 pounds was associated with a 65% reduc-
tion in cancer risk compared with women in the reference
group (OR = 0.35) (Table 4). A modest protective effect of this
degree of weight loss was also seen among BRCA2 mutation
carriers, although this association did not reach statistical sig-
nificance (OR = 0.88).
The mean baseline weight (weight at age 18) of the BRCA1
mutation carriers who lost more than 10 pounds was 142.5
pounds (range 115 to 230 pounds). These women experi-
enced a mean weight loss of 18.6 pounds (range 10 to 86
Table 2
Anthropometric variables in women with a deleterious BRCA1 or BRCA2 mutationa
All Premenopausal Postmenopausal
Variable Cases 
n = 1073
Controls 
n = 1073
P Cases 
n = 817
Controls 
n = 817
P Cases 
n = 256
Controls 
n = 256
P
Weight (pounds)
At birth 7.1 (1.3) 7.1 (1.3) 0.67 NA NA NA NA NA NA
At age 18 120.6 (17.2) 122.3 (19.1) 0.03 121.5 (17.1) 122.9 (19.2) 0.11 117.8 (17.3) 120.4 (18.5) 0.10
At age 30c 130.9 (17.3) 131.2 (18.5) 0.75 131.9 (17.1) 132.2 (18.5) 0.87 127.9 (17.4) 128.6 (18.6) 0.69
At age 40d 137.7 (23.4) 137.7 (24.3) 0.99 139.7 (22.8) 138.7 (25.0) 0.63 135.3 (23.9) 136.5 (23.4) 0.59
Current height (inches) 64.2 (2.6) 64.3 (2.6) 0.44 64.3 (2.6) 64.5 ± 2.6 0.50 63.9 ± 2.7 63.7 ± 2.7 0.10
Body mass indexb
At age 18 (kg/m2) 20.57 (2.8) 20.77 (3.0) 0.10 20.65 (2.8) 20.74 (3.0) 0.52 20.31 (2.7) 20.88 (2.9) 0.03
At age 30 (kg/m2)c 22.35 (3.4) 22.32 (3.7) 0.88 22.44 (3.4) 22.33 (3.9) 0.56 22.08 (3.4) 22.31 (3.1) 0.43
At age 40 (kg/m2)d 23.77 (3.9) 23.73 (3.9) 0.88 24.06 (3.8) 23.67 (4.1) 0.26 23.42 (4.0) 23.80 (3.7) 0.29
Weight gain (pounds)
From age 18 to 30c 10.5 (15.2) 9.4 (17.0) 0.14 10.6 (15.1) 9.8 (18.2) 0.35 10.1 (15.7) 8.2 (13.0) 0.23
From age 30 to 40d 9.4 (12.5) 9.2 (13.3) 0.82 10.6 (12.5) 9.1 (15.3) 0.23 7.9 (12.3) 8.2 (10.5) 0.23
From age 18 to 40d 18.6 (19.5) 18.1 (20.4) 0.71 19.9 (20.2) 19.0 (22.1) 0.61 17.0 (18.6) 17.1 (18.2) 0.98
The subjects were women who did (case subjects) or did not (control subjects) have a diagnosis of invasive breast cancer. aP values are 
univariate and were derived using Student's t-test and include both BRCA1 and BRCA2 mutation carriers. Other values are means (standard 
deviations). bExcludes subjects with missing data on current height. cCalculated for pairs in which case subjects were diagnosed at age >30 
years. dCalculated for pairs in which case subjects were diagnosed at age >40 years. NA, not applicable.
Figure 1
Weight at various ages among BRCA mutation carriers according to  year of birth Weight at various ages among BRCA mutation carriers according to 
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pounds) between age 18 and 30. Forty percent of these
women had a mean baseline weight greater than 150 pounds
and 35% had a BMI greater than 25.
Changes in body weight between age 18 and 30, parity, 
and risk of breast cancer in BRCA mutation carriers
Because parity has been shown to modify the risk of breast
cancer in carriers [25], we next examined the risk of breast
cancer associated with weight gain but taking into account the
possible modifying effect of parity (Table 5). Compared with
those who experienced minimal changes in body weight (± 10
pounds), weight gain of greater than 10 pounds among
women who had at least two full-term pregnancies was signif-
icantly associated with an increase in the risk of breast cancer
(OR = 1.44). To discern whether increased parity per se was
associated with weight gain, we compared mean weight gain
among the carriers, according to parity. The mean weight gain
across the groups was similar (data not shown). Therefore, the
increased risk of breast cancer associated with parity and any
weight gain is not attributable to greater weight gain among
those who had higher parity. A modifying effect of parity and
weight gain was not seen among women with a BRCA2 muta-
tion (Table 5).
Discussion
We conducted our study to examine whether change in body
weight modifies the risk of breast cancer among women who
carry a deleterious BRCA1 or BRCA2 mutation. We found
that BRCA  mutation carriers who lost at least 10 pounds
between age 18 and 30 had a 34% reduction in the risk of
breast cancer. However, on stratification of the sample by age
of breast cancer diagnosis, this protective effect was only
observed among BRCA mutation carriers diagnosed between
age 30 and 40 and not for those diagnosed after age 40.
Although weight loss reduced the risk of breast cancer among
carriers of either mutation, this association remained signifi-
cant only for women with a BRCA1 mutation (OR = 0.35). A
large proportion of the group who experienced weight loss
had a baseline BMI of greater than 25, the BMI cut-point for
the classification of overweight individuals [26]. This suggests
that recommendations regarding weight loss should be tar-
geted towards those women who are considered to be over-
weight at age 18.
The role of early adult weight gain and subsequent risk of
breast cancer is not well defined. The majority of studies report
either no association or a decrease in risk with weight gain for
premenopausal women, and inconsistent results for postmen-
Table 3
Weight change and subsequent cancer risk: subjects stratified by their age at diagnosis of cancer
Weight change between age 18 and 30 years Cases (number) Controls (number) ORa (95% CI) PP   for trend
In all subjectsb 966 966
Loss of at least 10 pounds 53 81 0.66 (0.46–0.93) 0.03
Loss of <10 to gain of ≤ 10 pounds 536 542 1 (referent)
Gain of 10 to ≤ 20 pounds 227 190 1.19 (0.96–1.49) 0.12
Gain of > 20 pounds 150 135 1.00 (0.77–1.30) 0.99 0.46
According to case subjects' age at diagnosis
>30 to ≤ 40 yearsc 478 478
Loss of at least 10 pounds 23 49 0.47 (0.28–0.79) 0.005
Loss of <10 to gain of ≤ 10 poundsd 255 254 1 (referent)
Gain of 10 to ≤ 20 pounds 112 89 1.25 (0.91–1.71) 0.17
Gain of >20 pounds 88 86 1.03 (0.72–1.47) 0.88 0.48
>40 yearsd 488 488
Loss of at least 10 pounds 30 32 0.97 (0.52–1.65) 0.91
Loss of <10 to gain of ≤ 10 poundsd 281 288 1 (referent)
Gain of 10 to ≤ 20 pounds 115 101 1.16 (0.85–1.59) 0.36
Gain of >20 pounds 62 67 0.95 (0.64–1.43) 0.82 0.75
Subjects were women with a deleterious mutation in BRCA1 or BRCA2 who did (case subjects) or did not (control subjects) receive a diagnosis 
of cancer. aAll odds ratios (ORs) were derived using univariate conditional logistic regression. bExcludes case subjects diagnosed at age ≤ 30 
years. cExcludes case subjects diagnosed at age ≤ 30 and >40 years. dExcludes case subjects diagnosed at ≤ 40 years. CI, confidence interval.Available online http://breast-cancer-research.com/content/7/5/R833
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opausal women [19,21]. It has been suggested that adult
weight gain may be a better measure of adiposity than BMI,
because lean body mass decreases with age [27] and BMI
does not distinguish between lean and fat mass; whereas
changes in adult weight largely reflect changes in body fat
[19,28]. Adult weight gain appears to be a consistent and
independent predictor of postmenopausal breast cancer risk,
particularly in women who never used hormone replacement
therapy [21,29-31]. Studies of adult weight gain and the risk
of premenopausal breast cancer have generally shown a
reduction in risk, although two studies found no association
[21,32]. In our selected study population as a whole, weight
gain did not influence risk. Rather, we observed a decrease in
the risk of breast cancer diagnosed between age 31 and 40
associated with weight loss in early adulthood (between age
18 and 30). Weight change that occurred between age 30
and 40 did not influence the subsequent risk of either
premenopausal or postmenopausal breast cancer. Our find-
ings suggest an important effect of weight loss in early years
and the risk of early-onset breast cancer. This effect is of par-
ticular relevance to our study population, because a character-
istic feature of BRCA-associated breast cancers is young age
at diagnosis [33].
Our findings suggest that in BRCA carriers, changes in body
weight throughout early adult life may have a more important
influence on the risk of early-onset breast cancer than current
weight or BMI [21]. The magnitude of the decreased risk asso-
ciated with weight loss compared with those women whose
weight remained stable was relatively large (OR = 0.47) (see
Table 3). After stratification by mutation status, the protective
effect of weight loss between age 18 and 30 was seen to be
less strong among women with a BRCA2 mutation. These
findings suggest that the timing of weight loss may play a more
important role in BRCA1-associated than in BRCA2-associ-
ated carcinogenesis, though the lack of a significant finding for
the latter group might also be attributable to a smaller sample
size. The effect may be of greater importance for women
belonging to more recent birth cohorts, since there appears to
be a greater increase in average weight at ages 30 and 40
with each decade (see Fig. 1).
We also found that in the subgroup of BRCA1 mutation carri-
ers who gained 10 pounds or more and who had at least two
full-term pregnancies, there was a 44% increase in their risk of
breast cancer. The modifying effects of both parity and weight
gain were not observed for women with a BRCA2 mutation.
The number of births did not influence the amount of weight
gain experienced by either the case or the control subjects,
providing confirmation that weight gain is not a surrogate for
parity or vice versa. Although pregnancy itself offers long-term
protection against postmenopausal breast cancer in the gen-
eral population, significant weight gain during pregnancy has
been associated with an increased risk of developing breast
cancer after the menopause [34]. We have reported else-
where that parity is a risk factor for breast cancer in BRCA2
carriers but not in BRCA1 carriers [25].
Ballard-Barbash proposed that weight change that occurs
during periods of noticeable hormonal change (i.e. menarche,
pregnancy, and menopause) may be attributed to host meta-
bolic factors that may also influence breast cancer risk [21]. In
addition, weight gain may result in differing biological effects
depending on the body fat distribution [21]. Weight gain dur-
ing pregnancy is characterized by an increase in central body
fat deposition [35]. The physiological consequences of upper
Table 4
Weight change and subsequent cancer risk: subjects stratified by their BRCA mutation
Weight change between age 18 and 30 years Cases (n) Controls (n) ORa (95% CI) PP   for trend
In BRCA1 mutation carriers 370 370
Loss of at least 10 pounds 13 38 0.35 (0.18–0.67) 0.002
Loss of <10 to gain of ≤ 10 poundsd 188 189 1 (referent)
Gain of 10 to ≤ 20 pounds 93 72 1.29 (0.91–1.83) 0.15
Gain of >20 pounds 76 71 1.09 (0.73–1.62) 0.67 0.34
In BRCA2 mutation carriers 108 108
Loss of at least 10 pounds 10 11 0.88 (0.35–2.23) 0.78
Loss of <10 to gain of ≤ 10 poundsd 67 65 1 (referent)
Gain of 10 to ≤ 20 pounds 19 17 1.08 (0.50–2.35) 0.84
Gain of >20 pounds 12 15 0.77 (0.33–1.81) 0.55 0.70
Subjects were women with a deleterious mutation in BRCA1 or BRCA2 who did (case subjects) or did not (matched control subjects) receive a 
diagnosis of breast cancer at age 30 to 39 years. aAll odds ratios (ORs) were derived using univariate conditional logistic regression. CI, 
confidence interval.Breast Cancer Research    Vol 7 No 5    Kotsopoulos et al.
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or central body fat localization include altered ovarian hormone
and glucose metabolism, as well as insulin resistance and
hyperinsulinemia, all of which may increase breast cancer risk
[21,36]. This pattern of fat distribution has been suggested to
pose a higher risk of breast cancer, independent of weight
[22,37].
Only two studies have evaluated the association between
anthropometric risk factors or physical activity and the risk of
breast cancer in BRCA1 and/or BRCA2 carriers [4,38]. King
and colleagues recently reported that a healthy weight defined
at menarche and at age 21, as well as physical activity during
adolescence, were associated with a significant delay in the
age of onset of breast cancer in BRCA1 and BRCA2 carriers;
however, such an effect could be attributable to either weight
gain increasing the risk of early-onset breast cancer or to
weight gain protecting against late-onset breast cancer [4]. An
earlier study of 46 BRCA1 carriers found no significant effect
of current BMI on the age at disease onset; however, the sam-
ple size was small [38].
The role of sex hormones in the etiology of breast cancer has
been well established [23]. It is generally agreed that increas-
ing levels of circulating estrogen are a determinant of obesity-
associated breast cancer in postmenopausal women [39]. In
contrast, most investigations of premenopausal women report
an inverse association between weight (or BMI or weight gain)
and the risk of breast cancer. The epidemiological evidence
suggests a positive association between these anthropomet-
ric variables and the risk of postmenopausal breast cancer
(reviewed in [17]). The primary hypothesis underlying this rela-
tion between menopausal status and the risk of breast cancer
is believed to involve an alteration in the source and levels of
endogenous sex hormones [19,40]. Before menopause, the
ovaries are the primary site of endogenous hormone produc-
tion. Since obesity has been shown to induce chronic anovu-
latory cycles and subsequently lower serum estrogen [41] and
progesterone levels [42], a decrease in hormone exposure is
believed to be the primary mechanism by which overweight
women may be protected against premenopausal breast can-
cer [43]. Extraglandular aromatization of androstenedione to
estrone occurs in the adipose tissue and is the primary source
of estradiol in postmenopausal women [39]. This conversion
of androgens and subsequent increase in estrogen levels has
been shown to be directly proportional to the amount of adi-
pose tissue [44] and the induction of aromatase activity which
may possibly enhance estrogen production in adipose tissue
[45]. In contrast, among BRCA carriers, weight gain did not
affect the risk of breast cancer.
Other metabolic consequences of obesity, more specifically
central adiposity, that have been suggested to be factors in
the development of breast cancer include hyperinsulinemia
and insulin resistance, as well as elevated levels of glucose
and triglycerides [46-50]. Obesity has also been shown to
increase testosterone [51,52] and leptin levels, [53,54] and to
depress sex-hormone-binding globulin concentrations. This
globulin is the predominant carrier of estradiol levels in both
premenopausal and postmenopausal women and is the pri-
mary protein responsible for binding and inactivating estradiol
Table 5
Weight change and subsequent cancer risk: subjectsa stratified by BRCA mutation and parity
Weight change between age 18 and 30 years Cases (number) Controls (number) ORc (95% CI) PP   for trendd
In BRCA1 mutation carriers
Loss of <10 to gain of ≤ 10 poundsb 188 189 1 (referent)
Gain of >10 pounds
Parity = 0 24 28 0.88 (0.50–1.55) 0.66
Parity = 1 26 27 0.94 (0.52–1.72) 0.85
Parity ≥ 2 117 84 1.44 (1.01–2.04) 0.04 0.16
Parity unknown 2 4
In BRCA2 mutation carriers
Loss of <10 to gain of ≤ 10 poundsb 67 65 1 (referent)
Gain of >10 pounds
Parity = 0 6 4 1.44 (0.40–5.13) 0.58
Parity = 1 7 6 1.10 (0.33–3.72) 0.87
Parity ≥ 2 18 22 0.73 (0.33–1.64) 0.45 0.31
Parity unknown 0 0
aWhose cancer was diagnosed when they were 30 to 39 years old. bA negative number indicates weight loss. cAll ORs were derived using 
univariate conditional logistic regression. dExcludes subjects in the weight-gain ≤ -10 group.Available online http://breast-cancer-research.com/content/7/5/R833
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[41,55,56]. Therefore, reducing the concentration of sex-hor-
mone-binding globulin may lead to an increase in the amount
of unbound, free estradiol.
High concentrations of circulating insulin-like growth factor1
(IGF-1) appears to be a risk factor for premenopausal breast
cancer in the general population, yet no such relation has been
observed for postmenopausal breast cancer [57]. Studies
have shown that both insulin and IGF-1 exert a mitogenic
effect by stimulating cell proliferation and inhibiting apoptosis
of breast cancer cells [58,59]. More importantly, it has been
suggested that IGF-1 may also work synergistically with other
growth factors and hormones, including estrogen, to further
promote cell proliferation [60]. Although both BMI and IGF-1
levels are suggested to influence breast cancer risk, studies
have generally shown no association or an inverse association
between BMI and circulating IGF-1 levels [60].
Both birthweight [61,62] and height [63] are positively asso-
ciated with IGF-1 levels. The evidence, primarily from cohort
studies, supports a positive association between birthweight
and the risk of breast cancer (reviewed in [64]) suggesting
that prenatal events may influence later risk. Adult height has
also been shown to positively predict the risk of breast cancer
in both pre- and postmenopausal women [18,32]. In our study,
there was no significant difference in birthweight between the
cases and controls and it seems unlikely that this variable influ-
ences risk in BRCA mutation carriers. Current height was not
associated with the risk of breast cancer, and this observation
is in agreement with a pooled analysis of 52 epidemiological
studies whereas height did not modify risk in women who had
one or more affected first-degree relatives in comparison with
women who had no affected relatives [65].
A potential drawback of our study was the use of self-reported
risk factor data, which may have introduced measurement
error and led to a spurious result or attenuation of results.
However, validation studies have shown that current and
recalled self-reported weight and height measurements are
highly correlated with measured data [66-72]. Self-reporting
many years prior has still been shown to retain a high degree
of validity [19]. Our data was collected on average 9 years
after the breast cancer diagnosis of the case, and 30 years
after age 18 (the first weight reported). There is a potential for
recall bias but there is no evidence of this in Table 2. The mean
weights at each reported age were similar and the differences
were not significant. In fact, the reported weight at age 18 was
less for cases than controls (we might expect recall bias to
generate the opposite result). Also, the dissimilar results for
BRCA1 and BRCA2 carriers argues against recall bias.
Despite the primary limitation of recall bias and other inherent
limitations associated with the use of case–control studies,
the primary strength of our study is the large sample of known
BRCA mutation carriers. This study involved 1,073 matched
pairs selected from a total of approximately 3,291 docu-
mented mutation carriers and is by far the largest study
addressing the role of anthropometric measures on the risk of
hereditary breast cancer. Our matching strategy and exclusion
criteria resulted in case and control groups that were similar in
most respects. We believe that our study participants are rep-
resentative of women who have had BRCA mutations identi-
fied during the course of genetic counselling. Our study was
based on known mutation carriers and included patients from
numerous participating centers and of different ethnic
backgrounds.
Conclusion
Our findings suggest that weight loss in early adult life (and
not weight per se) decreases the risk of BRCA-associated
breast cancer diagnosed at an early age. More specifically, the
period between age 18 and 30 years appears to be a critical
one when weight gain should be avoided in mutation carriers.
The effect may be greatest in BRCA1 carriers experiencing at
least two full-term pregnancies, but further study is necessary
to confirm this subgroup analysis. The maintenance of a
healthy weight during early adult life represents a potentially
modifiable risk factor in hereditary breast cancer syndromes.
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